BioSpace News Archive

Zenith Epigenetics Ltd. (“Zenith” or the “Company”) announced today the initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) clinical trial combining ZEN-3694 + Pfizer Inc.’s Talzenna (talazoparib).

Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) today provided company updates and reported consolidated first quarter 2022 financial results.

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”), a clinical-stage, biopharmaceutical company today announced that management will report first quarter 2022 financial results prior to the market open on May 16, 2022.

OncoNano Medicine, Inc. today announced the appointment of Elina Lavit as Vice President, Business Development.

Cortexyme, Inc. today announced that it entered into an agreement under which the company plans to acquire Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skeletal diseases, bone cancer and injury.

Twist Bioscience Corporation announced that Steffen Hellmold, senior vice president, business development for data storage, will participate in the 2022 Materials Research Society Spring Meeting and Exhibit taking place in Honolulu, Hawai’i May 8-13 and virtually May 23-25.

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (“Sonnet” or the “Company”), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three and six months ended March 31, 2022 and provided a business update.

Celsion Corporation, a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, provided an update on the progress made in the Company’s two lead development programs.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, announced the presentation of new positive outcomes in patients with refractory vulvovaginal candidiasis (VVC) treated with oral ibrexafungerp from the ongoing Phase 3 FURI study.

Moleculin Biotech, Inc. today announced that it has received approval from the United Kingdom’s (UK) MHRA to proceed with a first-in-human Phase 1a study to evaluate the safety and pharmacokinetics of WP1122 in healthy volunteers for the treatment of COVID-19 (MB-301).